Evaluation of the effect of 1,3-bis-(4-phenyl-[1,2,3] triazole-1-il)2-propanol in comparison with metronidazole in an in vitro culture of Blastocystis in samples of patients with irritable bowel syndrome

AbstractMetronidazole is the most-used pharmaceutical for the treatment of infection byBlastocystis. However, studies have reported resistance of the microorganism towards this pharmaceutical. In Mexico, studies concerning the prevalence of this parasite and its relationship to Irritable Bowel Syndrome have been carried out. To evaluate the in vitro effect of metronidazole and the compound 1,3-bis-(4-phenyl-[1,2,3] triazole-1-il)2-propanol overBlastocystis, as well as the prevalence ofBlastocystis in patients with Irritable Bowel Syndrome. A prospective, transversal design study (April 2016 –April 2017) of 51 samples of patients with Irritable Bowel Syndrome, obtained from the ISSEMyM Medical Center in Toluca, Mexico. For the identification ofBlastocystis was done in three serial stool samples through direct microscopic examination and the Ritchie technique. The in vitro susceptibility test towards metronidazole and the triazolic compound was done through a microculture in concentrations of 1 to 1000  µg/mL, each one in triplicate. A 31.3% prevalence ofBlastocystis was observed in the population, with greater prevalence in women (30.2%) than in men (25%). In the susceptibility test, a CL50 of 64  µg/mL was obtained for metronidazole, in comparison to the CL50 of 250  µg/mL for 1,3-bis-(4-phenyl-[1,2,3] triazole-1-il)2-propanol. This molecule in development has an effect for the treatment of infection byBlastocystis in vitro in patients with IBS and therefore, more stu...
Source: Journal of Parasitic Diseases - Category: Parasitology Source Type: research